MTOR and type 2 diabetes mellitus: Additionally, glucotoxicity caused by chronic hyperglycaemia and impaired branched-chain amino acid metabolism in patients with T2D further promotes MASH progression via mammalian target of rapamycin (mTOR) signalling.11